Acumen Pharmaceuticals Shares Up on Positive Alzheimer's Drug Data, $35.8M Private Placement

Dow Jones

Mar 16

By Adriano Marchese

Acumen Pharmaceuticals shares rose in premarket trading Monday after it said it had positive preclinical data for its Alzheimer's disease treatment and said it expects to raise $35.8 million in a private placement.

Shares traded 30% higher ahead of the morning bell at $4.26.

The clinical-stage biopharmaceutical company said on Monday that new preclinical results from its Enhanced Brain Delivery program showed that its experimental antibody candidates reached far higher brain levels in nonhuman primates than standard antibodies. They also showed no signs of anemia in blood tests, and appeared suitable for injection under the skin, it said.

The company aims to file an investigational new drug application for its lead candidate by mid-2027.

Acumen also said it plans to raise the $35.8 million through a private placement with certain institutional and accredited investors where it will sell its shares at a price of $3.30 per share.

The stock has performed well so far in 2026, rising 55% since the start of the year to close on Friday at $3.27 a share.

The funds will be used to support its Enhanced Brain Delivery program, including continuing preclinical work to select a lead drug candidate. The money will also go toward general operating needs.

Write to Adriano Marchese at adriano.marchese@wsj.com

(END) Dow Jones Newswires

March 16, 2026 07:17 ET (11:17 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2619245752"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2619245752\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2619245752?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-16 19:17","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2619245752","market":"us","top_or_hot":-1,"title":"Acumen Pharmaceuticals Shares Up on Positive Alzheimer's Drug Data, $35.8M Private Placement","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Adriano Marchese \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Acumen Pharmaceuticals shares rose in premarket trading Monday after it said it had positive preclinical data for its Alzheimer's disease treatment and said it expects to raise $35.8 million in a private placement. \n</p>\n<p>\n  Shares traded 30% higher ahead of the morning bell at $4.26. \n</p>\n<p>\n  The clinical-stage biopharmaceutical company said on Monday that new preclinical results from its Enhanced Brain Delivery program showed that its experimental antibody candidates reached far higher brain levels in nonhuman primates than standard antibodies. They also showed no signs of anemia in blood tests, and appeared suitable for injection under the skin, it said. \n</p>\n<p>\n  The company aims to file an investigational new drug application for its lead candidate by mid-2027. \n</p>\n<p>\n  Acumen also said it plans to raise the $35.8 million through a private placement with certain institutional and accredited investors where it will sell its shares at a price of $3.30 per share. \n</p>\n<p>\n  The stock has performed well so far in 2026, rising 55% since the start of the year to close on Friday at $3.27 a share. \n</p>\n<p>\n  The funds will be used to support its Enhanced Brain Delivery program, including continuing preclinical work to select a lead drug candidate. The money will also go toward general operating needs. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Adriano Marchese at adriano.marchese@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  March 16, 2026 07:17 ET (11:17 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Acumen Pharmaceuticals Shares Up on Positive Alzheimer's Drug Data, $35.8M Private Placement</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAcumen Pharmaceuticals Shares Up on Positive Alzheimer's Drug Data, $35.8M Private Placement\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-03-16 19:17</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Adriano Marchese \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Acumen Pharmaceuticals shares rose in premarket trading Monday after it said it had positive preclinical data for its Alzheimer's disease treatment and said it expects to raise $35.8 million in a private placement. \n</p>\n<p>\n  Shares traded 30% higher ahead of the morning bell at $4.26. \n</p>\n<p>\n  The clinical-stage biopharmaceutical company said on Monday that new preclinical results from its Enhanced Brain Delivery program showed that its experimental antibody candidates reached far higher brain levels in nonhuman primates than standard antibodies. They also showed no signs of anemia in blood tests, and appeared suitable for injection under the skin, it said. \n</p>\n<p>\n  The company aims to file an investigational new drug application for its lead candidate by mid-2027. \n</p>\n<p>\n  Acumen also said it plans to raise the $35.8 million through a private placement with certain institutional and accredited investors where it will sell its shares at a price of $3.30 per share. \n</p>\n<p>\n  The stock has performed well so far in 2026, rising 55% since the start of the year to close on Friday at $3.27 a share. \n</p>\n<p>\n  The funds will be used to support its Enhanced Brain Delivery program, including continuing preclinical work to select a lead drug candidate. The money will also go toward general operating needs. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Adriano Marchese at adriano.marchese@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  March 16, 2026 07:17 ET (11:17 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4539","symbol_name":"次新股","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2619245752","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2619245752","pubTimestamp":1773659820,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Acumen Pharmaceuticals shares rose in premarket trading Monday after it said it had positive preclinical data for its Alzheimer's disease treatment and said it expects to raise $35.8 million in a private placement.Shares traded 30% higher ahead of the morning bell at $4.26.The clinical-stage biopharmaceutical company said on Monday that new preclinical results from its Enhanced Brain Delivery program showed that its experimental antibody candidates reached far higher brain levels in nonhuman primates than standard antibodies. They also showed no signs of anemia in blood tests, and appeared suitable for injection under the skin, it said.The company aims to file an investigational new drug application for its lead candidate by mid-2027.Acumen also said it plans to raise the $35.8 million through a private placement with certain institutional and accredited investors where it will sell its shares at a price of $3.30 per share.The stock has performed well so far in 2026, rising 55% since t","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4539":"次新股","ABOS":"Acumen Pharmaceuticals, Inc.","BK4139":"生物科技"},"translate_title":"Acumen Pharmaceuticals因积极的阿尔茨海默病药物数据而股价上涨，私募3580万美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ABOS":1.5},"content_text":"By Adriano Marchese \n\n\n \n\n\n  Acumen Pharmaceuticals shares rose in premarket trading Monday after it said it had positive preclinical data for its Alzheimer's disease treatment and said it expects to raise $35.8 million in a private placement. \n\n\n  Shares traded 30% higher ahead of the morning bell at $4.26. \n\n\n  The clinical-stage biopharmaceutical company said on Monday that new preclinical results from its Enhanced Brain Delivery program showed that its experimental antibody candidates reached far higher brain levels in nonhuman primates than standard antibodies. They also showed no signs of anemia in blood tests, and appeared suitable for injection under the skin, it said. \n\n\n  The company aims to file an investigational new drug application for its lead candidate by mid-2027. \n\n\n  Acumen also said it plans to raise the $35.8 million through a private placement with certain institutional and accredited investors where it will sell its shares at a price of $3.30 per share. \n\n\n  The stock has performed well so far in 2026, rising 55% since the start of the year to close on Friday at $3.27 a share. \n\n\n  The funds will be used to support its Enhanced Brain Delivery program, including continuing preclinical work to select a lead drug candidate. The money will also go toward general operating needs. \n\n\n \n\n\n  Write to Adriano Marchese at adriano.marchese@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 16, 2026 07:17 ET (11:17 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}